- Home
- GOVX vs SYNX Comparison
GOVX vs SYNX Comparison
Compare GOVX & SYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- SYNX
- Stock Information
- Founded
- GOVX 2001
- SYNX 2005
- Country
- GOVX United States
- SYNX Israel
- Employees
- GOVX N/A
- SYNX N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- SYNX
- Sector
- GOVX Health Care
- SYNX
- Exchange
- GOVX Nasdaq
- SYNX Nasdaq
- Market Cap
- GOVX 15.5M
- SYNX 13.7M
- IPO Year
- GOVX N/A
- SYNX 2024
- Fundamental
- Price
- GOVX $0.95
- SYNX $1.74
- Analyst Decision
- GOVX Strong Buy
- SYNX
- Analyst Count
- GOVX 5
- SYNX 0
- Target Price
- GOVX $12.40
- SYNX N/A
- AVG Volume (30 Days)
- GOVX 1.5M
- SYNX 127.8K
- Earning Date
- GOVX 08-05-2025
- SYNX 05-14-2025
- Dividend Yield
- GOVX N/A
- SYNX N/A
- EPS Growth
- GOVX N/A
- SYNX N/A
- EPS
- GOVX N/A
- SYNX N/A
- Revenue
- GOVX $5,591,576.00
- SYNX $9,094,000.00
- Revenue This Year
- GOVX N/A
- SYNX $32.35
- Revenue Next Year
- GOVX N/A
- SYNX N/A
- P/E Ratio
- GOVX N/A
- SYNX N/A
- Revenue Growth
- GOVX N/A
- SYNX 19.14
- 52 Week Low
- GOVX $0.73
- SYNX $1.65
- 52 Week High
- GOVX $11.18
- SYNX $6.49
- Technical
- Relative Strength Index (RSI)
- GOVX 46.22
- SYNX 48.15
- Support Level
- GOVX $0.85
- SYNX $1.67
- Resistance Level
- GOVX $1.39
- SYNX $1.91
- Average True Range (ATR)
- GOVX 0.15
- SYNX 0.20
- MACD
- GOVX -0.02
- SYNX 0.02
- Stochastic Oscillator
- GOVX 18.52
- SYNX 22.21
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.